Sangui Biotech International (Sangui Biotech International) Change In Receivables : $-0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Change In Receivables?

Sangui Biotech International's change in receivables for the quarter that ended in Mar. 2023 was $-0.01 Mil. It means Sangui Biotech International's Accounts Receivable increased by $0.01 Mil from Dec. 2022 to Mar. 2023 .

Sangui Biotech International's change in receivables for the fiscal year that ended in Jun. 2022 was $0.00 Mil. It means Sangui Biotech International's Accounts Receivable declined by $0.00 Mil from Jun. 2021 to Jun. 2022 .

Sangui Biotech International's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.02 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sangui Biotech International's Days Sales Outstanding for the three months ended in Mar. 2023 was 110.46.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sangui Biotech International's liquidation value for the three months ended in Mar. 2023 was $-1.07 Mil.

Sangui Biotech International Change In Receivables Historical Data

The historical data trend for Sangui Biotech International's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Change In Receivables Chart

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Change In Receivables

Get a 7-Day Free Trial

-0.05

0.01

0.02

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Receivables	Get a 7-Day Free Trial															-	0.01	-0.04	0.04	-0.01

Sangui Biotech International Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Sangui Biotech International (OTCPK:SGBI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sangui Biotech International's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.023	/	0.019	*	91
=	110.46

2. In Ben Graham's calculation of liquidation value, Sangui Biotech International's accounts receivable are only considered to be worth 75% of book value:

Sangui Biotech International's liquidation value for the quarter that ended in Mar. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.007	-	1.099	+	0.75 * 0.023	+	0.5 * 0
=	-1.07

Sangui Biotech International Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines